Sotera Health Co stock (US8293551086): Sponsors exit with 31.8M share sale, agreement terminated

Sotera Health Co's prior private equity sponsors Warburg Pincus and GTCR fully exited via a 31.8 million share secondary offering at $15.168 per share, closing May 13, 2026. This terminated the Stockholders Agreement, ending special governance rights, per SEC filing.

Sotera Health Co disclosed that affiliates of Warburg Pincus LLC and GTCR LLC sold 31,838,253 shares of common stock at $15.168 per share in a secondary offering underwritten by Goldman Sachs & Co. LLC. The transaction closed on May 13, 2026, with the company receiving no proceeds as it did not issue new shares. Following the sale, the sponsors own no common stock, automatically terminating the existing Stockholders Agreement and their special rights, including director designations, according to the SEC filing as of 05/13/2026 and Reuters as of 05/13/2026.

Sotera Health Co (Nasdaq: SHC) traded with elevated volume amid the news, showing 4.8 times normal activity on May 13, 2026, per market data. The stock was at approximately $15.17 in recent trading on Nasdaq, according to exchange records as of 05/13/2026. This sponsor exit marks a shift to broader public ownership for the healthcare services provider.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Sotera Health Company
• Sector/industry: Healthcare services (sterilization and lab testing)
• Headquarters/country: Broadview Heights, OH, USA
• Core markets: Medical devices, pharmaceuticals, food safety
• Key revenue drivers: Sterigenics, Nordion, Nelson Labs segments
• Home exchange/listing venue: Nasdaq (SHC)
• Trading currency: USD

Sotera Health Co: core business model

Sotera Health Co provides mission-critical sterilization solutions, lab testing, and advisory services to the healthcare industry worldwide. Its three main segments—Sterigenics, Nordion, and Nelson Labs—serve medical device, pharmaceutical, food safety, and advanced materials markets. Sterigenics offers outsourced terminal sterilization using gamma irradiation, ethylene oxide, and E-beam technologies, as detailed in company disclosures.

Nordion supplies cobalt-60 sources for sterilization and irradiation, plus gamma systems, supporting cancer treatment applications. Nelson Labs delivers microbiological and analytical chemistry testing for medical and pharma clients. This integrated model positions Sotera Health Co as essential for regulatory compliance in healthcare supply chains, with significant exposure to US markets via Nasdaq listing.

Main revenue and product drivers for Sotera Health Co

The Sterigenics segment drives the bulk of revenue through contract sterilization services for US and global clients in medical devices and pharmaceuticals. Nordion's Co-60 sales benefit from steady demand in irradiation processes, while Nelson Labs grows via expanded testing capacities. These drivers align with rising healthcare standards, per investor presentations on IR site as of 05/2026.

US investors note Sotera Health Co's role in the domestic medtech ecosystem, where sterilization is mandatory for FDA approvals. The recent sponsor exit simplifies governance, potentially aiding strategic flexibility without private equity influence.

Industry trends and competitive position

The sterilization services market expands with medtech innovation and supply chain localization post-pandemic. Sotera Health Co holds a leading position via its multi-modal tech portfolio, differentiating from pure-play gamma or EO providers. Competitors face regulatory scrutiny on EO emissions, bolstering demand for diversified services like E-beam.

Why Sotera Health Co matters for US investors

Listed on Nasdaq, Sotera Health Co offers US investors exposure to defensive healthcare services with recurring contract revenue. Its US headquarters and facilities underpin sensitivity to FDA policies and domestic manufacturing trends, making it relevant amid onshoring pushes.

Conclusion

The termination of Sotera Health Co's Stockholders Agreement after the sponsors' full exit via the May 13, 2026, share sale ushers in a new phase of independent governance. With no ongoing sponsor influence, the company transitions to standard public company operations, while its core sterilization and testing businesses remain geared toward healthcare essentials. US investors will watch how board evolution and capital allocation proceed post-exit.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.